

Review of: "[Case Report] Supplementation with Vitamin D, Zinc, and Quercetin to Treat COVID-19: A Case Report"

Sahel Heydari¹

¹ Ahvaz Jundishapur University of Medical Sciences

Potential competing interests: No potential competing interests to declare.

Review Comments:

1. Comment: The abstract provides a concise overview of the case report, focusing on the treatment of a COVID-19 patient using a combination of vitamin D, zinc, and quercetin. The objective and clinical features are well-defined.
2. Comment: It would be helpful to provide more details regarding the patient's medical history, pre-existing conditions, and any medications taken prior to the supplementation. This additional information could help in understanding the context and potential factors that might have influenced the treatment outcome.
3. Comment: While the abstract mentions the improvement of symptoms after supplementation, it would be beneficial to include specific quantitative measurements or objective assessments to support the claim of symptom improvement. This would strengthen the credibility of the findings.
4. Comment: The abstract could benefit from discussing any potential limitations or adverse effects associated with the supplementation. Addressing these aspects would provide a more comprehensive view of the treatment approach and its potential implications.
5. Comment: It would be valuable to provide a brief discussion on the mechanisms of action of vitamin D, zinc, and quercetin in the context of COVID-19 treatment. This would enhance the understanding of how these components might contribute to symptom resolution.
6. Could you elaborate on the rationale behind choosing the specific dosages of vitamin D, zinc, and quercetin? Were these dosages based on previous studies or guidelines? Refer to the appropriate reference for this section " PMID: 36184235 "
7. Were any other treatment interventions or medications administered alongside the supplementation? If so, how were the potential interactions or synergistic effects considered in the treatment plan?
8. Was the patient's adherence to the supplementation regimen monitored closely? Were there any challenges or difficulties encountered during the treatment period?
9. Considering the limitations of this case report, how would you suggest future research be conducted to further investigate the efficacy of this supplementation approach in COVID-19 patients?

10. Were there any notable differences in the patient's laboratory parameters, such as inflammatory markers or immune response indicators, before and after the treatment?

11. For the following text the suitable references is suggested " The pathophysiology of COVID-19 may arise from the activation of various inflammatory markers. The virus up-regulates the gene expression of nuclear factor- κ B (NF- κ B) and by extension the proinflammatory arachidonic cascade and the production of proinflammatory eicosanoids.. " PMID: 33612539 "

12. The case report provides a comprehensive overview of the patient's symptoms and medical history. However, it would be helpful to include information about any pre-existing conditions or comorbidities that might have influenced the course of COVID-19 in this patient.

13. The use of a numeric scale to assess symptom severity is useful for quantifying the patient's experience. It would be beneficial to provide a brief explanation of the scale used and its validity/reliability in assessing cough, nasal congestion, fatigue, and other symptoms.

14. It's interesting to note that the patient received the Moderna vaccine and a booster prior to the onset of infection. Can you provide more details about the timing of these doses and whether they had any impact on the severity or duration of the patient's symptoms?

15. The patient's persistent cough, nasal congestion, and fatigue despite the resolution of other symptoms raise questions about potential long-term effects or complications associated with COVID-19. Have there been any studies or reports indicating similar lingering symptoms in individuals who have received the Moderna vaccine?

16. The impact of over-the-counter Advil usage on the course of COVID-19 symptoms is briefly mentioned. It would be helpful to elaborate on the rationale behind using Advil and discuss any potential interactions or effects it may have had on the patient's recovery.

17. Were there any notable findings from physical examination or diagnostic tests conducted during the telehealth call that might contribute to our understanding of the patient's condition?

18. In terms of the patient's vaccination history, were there any specific reasons for choosing the Moderna vaccine over other available options?

19. Considering the patient's age and relatively recent vaccination history, did the healthcare provider discuss the possibility of breakthrough infections and their potential impact on symptom severity?

20. Did the patient have any known contact with individuals who had tested positive for COVID-19 prior to her own infection? How might this have influenced the course of her symptoms?

